Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study

被引：0
|
作者：
Cavender, M. A. [1 ]
Norhammar, A. [2 ]
Birkeland, K. I. [3 ,4 ]
Jorgensen, M. E. [5 ]
Wilding, P. [6 ]
Khunti, K. [7 ]
Fu, A. Z. [8 ]
Bodegard, J. [9 ]
Blak, B. [10 ]
Wittbrodt, E. T. [11 ]
Thuresson, M. [12 ]
Fenici, P. [13 ]
Hammar, N. [2 ,14 ]
Kosiborod, M. [15 ,16 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Karolinska Inst, Stockholm, Sweden
[3] Univ Oslo, Oslo, Norway
[4] Oslo Univ Hosp, Oslo, Norway
[5] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[6] Inst Ageing & Chron Dis, Liverpool, Merseyside, England
[7] Univ Leicester, Leicester, Leics, England
[8] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[9] AstraZeneca, Oslo, Norway
[10] AstraZeneca, Luton, Beds, England
[11] AstraZeneca, Wilmington, DE USA
[12] Statisticon AB, Uppsala, Sweden
[13] AstraZeneca, Cambridge, England
[14] AstraZeneca Gothenburg, Molndal, Sweden
[15] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[16] Univ Missouri Kansas City, Kansas City, MO USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
88
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [1] Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease: CVD-REAL Study
    Cavender, Matthew A.
    Norhammar, Anna
    Birkeland, Kare I.
    Jorgensen, Marit Eika
    Wilding, John P. H.
    Khunti, Kamlesh
    Fu, Alex Z.
    Bodegard, Johan
    Blak, Betina T.
    Wittbrodt, Eric T.
    Thuresson, Marcus
    Fenici, Peter
    Hammar, Niklas
    Kosiborod, Mikhail N.
    DIABETES, 2017, 66 : A99 - A100
  • [2] CARDIOVASCULAR DISEASE SGLT-2 inhibitors in heart failure: a new therapeutic avenue
    Vaduganathan, Muthiah
    Butler, Javed
    NATURE MEDICINE, 2019, 25 (11) : 1653 - 1654
  • [3] SGLT-2 inhibitors in frail patients with heart failure
    Charansonney, Olivier Luc
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 352 : 102 - 103
  • [4] SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis
    Razuk, V.
    Chiarito, M.
    Cao, D.
    Nicolas, J.
    Camaj, A.
    Power, D.
    Beerkens, F.
    Tavenier, A. H.
    Pivato, C.
    Mehran, R.
    Dangas, G.
    EUROPEAN HEART JOURNAL, 2021, 42 : 916 - 916
  • [5] SGLT-2 inhibitors in heart failure: a new therapeutic avenue
    Muthiah Vaduganathan
    Javed Butler
    Nature Medicine, 2019, 25 : 1653 - 1654
  • [6] The use of SGLT-2 inhibitors and hemoconcentration in patients with heart failure
    Demir, E.
    Kose, R.
    Pirmammadova, F.
    Unlugenc, H.
    Gurgun, C.
    Nalbantgil, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 219 - 220
  • [7] SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis
    Razuk, Victor
    Chiarito, Mauro
    Cao, Davide
    Nicolas, Johny
    Pivato, Carlo A.
    Camaj, Anton
    Power, David
    Beerkens, Frans
    Jones, Davis
    Alter, Aviv
    Mathew, Alvin
    Spirito, Alessandro
    Contreras, Johanna P.
    Dangas, George D.
    Mehran, Roxana
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 557 - 567
  • [8] SGLT-2 Inhibitors for Cardiovascular Outcomes in Heart Failure With Preserved Ejection Fraction
    Carek, Stephen
    Yurgil, Jacqueline
    Mounsey, Anne
    AMERICAN FAMILY PHYSICIAN, 2023, 107 (01) : 81 - 82
  • [9] SGLT-2 Inhibitors Reduce Heart Failure-Related Hospitalization in Patients Without Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2022, 106 (04) : 461 - 462
  • [10] Meta-analysis of SGLT inhibitors on cardiovascular death or heart failure hospitalisation based on presence of type 2 diabetes, heart failure, or chronic kidney disease
    Charalampidis, K.
    Karagiannis, T.
    Liakos, A.
    Kakotrichi, P.
    Tsapas, A.
    Bekiari, E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 359 - 359
12345